Page 207 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

MUM1 0=negative, (<40%), 1=positive (>40%), 9=not available
GCB/ non GCB, 9=not available
MYC- BA 0=neg 1=pos
BCL2- BA 0=neg 1=pos
BCL6- BA 0=neg 1=pos
ABC/GCB/ undeterminate, 9=not available
WHO 2008
WHO 2017
100 75 50 25
Disease free survival from CR Rearrangement [single hit, double or triple hit]
NE single hit 19 5 double or triple hit 44 13
double or triple hit
single hit
Cumulative percentage
00 6 12 At risk:
single hit 19 15 14 double or triple hit 44 34 29 26 Jun 2019
18 months 2􏰀
7 5 21 15
7
1 non-GCB 1 0 1
1 GCB 1 0 0 nd GCB 1 1 0 0 GCB 1 0 1 0 GCB 1 0 0 9 GCB 1 1 1
ABC dd DLBCL or BCL-U
9 DLBCL
ABC DLBCL
GCB DLBCL poor quality BCL-U unclassified DLBCL
GCB DLBCL 9 DLBCL
dd DLBCL or HGBCL, NOS dd DLBCL or HGBCL, DH/TH HGBCL,DH/TH DLBCL HGBCL, DH/TH HGBCL,DH/TH DLBCL HGBCL,DH/TH
R-CHOP with lenalidomide in MYC+ LBCL
9 1
0
FISH
9 1 0 0 non-GCB 1 0 0
GCB 1 9 9
GEP Classification
ABC DLBCL DLBCL
Figure S1A
205